Spots Global Cancer Trial Database for A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
Official Title: A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Study ID: NCT04502446
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
Detailed Description: The study may enroll approximately 45 subjects in total.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site 2, Duarte, California, United States
Research Site 5, Stanford, California, United States
Research Site 10, New Haven, Connecticut, United States
Research Site 4, Miami, Florida, United States
Research Site 8, Bronx, New York, United States
Research Site 9, New York, New York, United States
Research Site 1, Houston, Texas, United States
Research Site 6, Salt Lake City, Utah, United States
Research Site 3, Sydney, New South Wales, Australia
Research Site 7, Toronto, Ontario, Canada
Contact Details
Name: Alissa Keegan, PhD
Affiliation: CRISPR Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
